What Patients Wish Doctors Knew About Breast Cancer Recurrence Risk

For many people diagnosed with early breast cancer, the end of active treatment does not mean the end of fear. A quiet worry—the possibility that the cancer might return—often lingers for years. One patient, Lina, who was diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at age 40, shares her story to help bridge the gap between what doctors know and what patients feel.

Lina was compensated for her time by Novartis, the company that makes a treatment she uses. But her message is clear: patients need doctors to understand that the risk of recurrence is not just a statistic. It is a daily reality that shapes how they live, plan, and hope.

The Hidden Weight of Recurrence Fear

Breast cancer recurrence is not always a loud, obvious fear. For many patients, it is a quiet presence that stays long after surgery, chemotherapy, and radiation are finished. Lina describes this feeling as a kind of uncertainty that can feel disorienting, even for someone who works in health care.

“I understood recurrence risk intellectually,” she says. “Still, nothing prepares you for the moment when statistics become personal.”

Breast cancer is rising fastest among women under 50, according to the American Cancer Society. Lina was 40 when she noticed something was wrong. Because of her age, mammograms were not yet routine for her. She kept pushing for one, and that decision changed everything. After her diagnosis of stage II HR+/HER2- early breast cancer, she went through chemotherapy, surgery, and radiation. When treatment ended, everyone around her celebrated. But she felt a new kind of fear settle in.

What the Numbers Say About Recurrence Risk

According to the Novartis Breast Health & Experience Index, a survey conducted by Harris Poll on behalf of Novartis, nearly 8 in 10 women in the United States with breast cancer worry about recurrence, even after surgery and initial treatment. Yet many patients hesitate to bring that worry into the exam room. Lina admits she did the same.

“During follow-up visits, I wanted to be seen as doing well,” she says. “Talking about recurrence felt like reopening something I was supposed to have closed.”

But those fears do not disappear just because patients stay quiet. The same survey found that nearly two-thirds of U.S. women with breast cancer feel there is more they could be doing to reduce their risk. And just as many wish they knew more about their treatment options.

For people with HR+/HER2- early breast cancer, the risk of recurrence can last for many years. Clinical studies show that up to 1 in 9 patients with node-negative disease (meaning the cancer has not spread to lymph nodes) may experience recurrence within the first three years. For those with node-positive disease (four or more affected nodes), up to 1 in 4 may recur within three years. Over a 20-year period, as many as half of patients may face recurrence.

These numbers may sound alarming, but experts say they highlight an important point: recurrence risk does not go away quickly, even when initial treatment appears successful. Understanding this long-term risk is critical when making decisions about follow-up care.

Why Patients Stay Quiet—And Why That Matters

Many patients want to be seen as “doing well” during follow-up visits. They do not want to seem ungrateful for surviving treatment. They may worry that bringing up fear will make them seem anxious or difficult. But experts say this silence can prevent important conversations about managing risk.

Lina learned that for some patients with HR+/HER2- early breast cancer, recurrence risk can persist for years after surgery or initial treatment. She was surprised to learn that having few or even no lymph nodes affected does not always mean the risk is low. This is because the cancer’s biology—its specific features—also matters.

“As I began looking ahead, conversations about my recurrence risk became central to my care,” she says.

What Doctors Can Do to Help

Lina hopes that doctors will create space for these conversations. She says many patients are thinking about recurrence long before they say it out loud. What they often need is permission to talk about the fears they are trying to carry quietly.

“Sometimes what patients need most is permission to talk about the fears they are trying hard to carry quietly,” she says.

Experts agree that open communication between patients and doctors is key. When patients understand their personal risk, they can make informed choices about treatment options. This is especially important for people with high-risk early breast cancer—meaning the cancer has features linked to a higher chance of recurrence, such as spreading to nearby lymph nodes or having more aggressive tumor features.

Treatment Options for High-Risk Patients

For people like Lina, who have high-risk HR+/HER2- early breast cancer, treatment options include a type of medication called a CDK4/6 inhibitor. One such drug is KISQALI (ribociclib), which is used in combination with an aromatase inhibitor (AI) for adults with stage II and III early breast cancer at high risk of recurrence.

Lina’s oncologist explained the difference between managing risk now and treating metastatic disease later. That distinction helped her understand the role of adjuvant therapy—treatment given after initial therapy to lower the chance of recurrence.

Starting treatment involved some trial and error, Lina says. But the once-daily rhythm of KISQALI, with a built-in week off between cycles, worked for her and helped her stay consistent. Just as important were the ongoing conversations with her oncologist.

“That partnership made treatment feel manageable,” she says.

Living with a New Normal

Two years after her diagnosis, Lina describes herself as living a new normal. She still misses parts of the person she was before cancer, but she also recognizes the strength that came from navigating uncertainty.

“The fear of recurrence does not disappear entirely,” she says. “But understanding my options and knowing I am doing my part makes me feel empowered about my treatment plan.”

For readers who are breast cancer survivors or who know someone with the disease, Lina’s story offers a few practical takeaways:

• It is normal to worry about recurrence, even years after treatment ends.
• Do not be afraid to bring up these fears with your doctor. They are part of your care.
• Ask about your personal risk factors, including the type and stage of your cancer.
• If you have high-risk features, ask whether adjuvant therapy might be right for you.
• Remember that you are an active participant in your care. Your voice matters.

Important Safety Information About KISQALI

KISQALI is a prescription medicine used with an aromatase inhibitor to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer that is stage II or III and has a high risk of coming back.

KISQALI can cause serious side effects, including:

• Lung problems: Severe, life-threatening, or fatal lung inflammation (interstitial lung disease or pneumonitis) can occur. Symptoms may include coughing, trouble breathing, and low oxygen levels. If you have new or worsening breathing problems, your doctor should stop KISQALI and check you right away.
• Severe skin reactions: Rare but serious skin reactions, including Stevens-Johnson syndrome, can occur. If you develop a rash, blisters, or peeling skin, tell your doctor immediately.
• Heart rhythm changes (QT prolongation): KISQALI can affect your heart’s electrical activity. Your doctor will check your heart with an ECG before and during treatment. Avoid KISQALI if you are at risk for a dangerous heart rhythm condition called torsades de pointes.
• Liver problems: Liver inflammation and injury can occur. Your doctor will check your liver function with blood tests before and during treatment.
• Low white blood cell counts (neutropenia): This is common and can increase your risk of infection. Your doctor will check your blood counts before and during treatment.
• Harm to unborn babies: KISQALI can cause harm to a fetus. Women who can become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose.

The most common side effects in patients with early breast cancer include infections, nausea, headache, and fatigue. In patients with advanced or metastatic breast cancer, common side effects also include diarrhea, vomiting, hair loss, cough, rash, and back pain.

These are not all the possible side effects. Talk to your doctor for more information.

Looking Ahead

Lina’s story is one of many. Across the country, patients with early breast cancer are navigating the long road after treatment. They are learning to live with uncertainty, to ask hard questions, and to find strength in partnership with their doctors.

For doctors, the message is simple: create space for these conversations. For patients, the message is just as clear: you are not alone, and your fears deserve to be heard.

To learn more about recurrence risk in early breast cancer and which patients may benefit from KISQALI, visit https://www.kisqali-hcp.com/early-breast-cancer/risk-of-recurrence.

Lina is currently being treated with KISQALI plus an aromatase inhibitor for HR+/HER2- early breast cancer and is a Voices of MORE ambassador. Novartis Pharmaceuticals Corporation has no control over third-party websites linked in this story and makes no representation as to the accuracy, completeness, or adequacy of the information on those sites.

This article was produced with support from Novartis. The MedPage Today Editorial team was not involved in the creation of this content.

Source: MedPage Today